Compare FNLC & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNLC | OBIO |
|---|---|---|
| Founded | 1864 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 415.5M | 362.4M |
| IPO Year | 1995 | 2020 |
| Metric | FNLC | OBIO |
|---|---|---|
| Price | $36.49 | $5.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $12.43 |
| AVG Volume (30 Days) | 33.6K | ★ 305.0K |
| Earning Date | 10-21-2026 | 11-13-2026 |
| Dividend Yield | ★ 4.13% | N/A |
| EPS Growth | 26.34 | ★ 33.13 |
| EPS | ★ 1.65 | N/A |
| Revenue | N/A | ★ $33,482,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $33.45 |
| P/E Ratio | $22.43 | ★ N/A |
| Revenue Growth | N/A | ★ 1169.22 |
| 52 Week Low | $24.63 | $3.46 |
| 52 Week High | $37.50 | $6.50 |
| Indicator | FNLC | OBIO |
|---|---|---|
| Relative Strength Index (RSI) | 68.52 | 51.62 |
| Support Level | $34.28 | $5.71 |
| Resistance Level | N/A | $6.38 |
| Average True Range (ATR) | 0.95 | 0.32 |
| MACD | 0.24 | 0.00 |
| Stochastic Oscillator | 88.47 | 57.50 |
First Bancorp Inc is a Damariscotta-based bank holding company providing a range of retail and commercial banking services, including deposit accounts and consumer, commercial, and mortgage loans. The company provides investment management and private banking services through an operating division of the bank. Its revenues are generally derived from dividends paid to the company by the bank.
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.